These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 25802726)
1. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. Yokoh H; Kobayashi K; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K J Diabetes Investig; 2015 Mar; 6(2):182-91. PubMed ID: 25802726 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P; Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K; Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P; Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [TBL] [Abstract][Full Text] [Related]
5. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M; Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856 [TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H; Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668 [TBL] [Abstract][Full Text] [Related]
7. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. Kadowaki T; Tajima N; Odawara M; Nishii M; Taniguchi T; Ferreira JC J Diabetes Investig; 2013 Mar; 4(2):174-81. PubMed ID: 24843649 [TBL] [Abstract][Full Text] [Related]
8. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. Kashiwagi A; Kadowaki T; Tajima N; Nonaka K; Taniguchi T; Nishii M; Ferreira JC; Amatruda JM J Diabetes Investig; 2011 Oct; 2(5):381-90. PubMed ID: 24843518 [TBL] [Abstract][Full Text] [Related]
9. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525 [TBL] [Abstract][Full Text] [Related]
10. Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial. Zhang F; Tang L; Li J; Yan Z; Li J; Tong N Diabetes Metab Syndr Obes; 2021; 14():1243-1252. PubMed ID: 33776461 [TBL] [Abstract][Full Text] [Related]
11. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Srivastava S; Saxena GN; Keshwani P; Gupta R J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111 [TBL] [Abstract][Full Text] [Related]
12. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Choy M; Lam S Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732 [TBL] [Abstract][Full Text] [Related]
14. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. Kim HS; Kim DM; Cha BS; Park TS; Kim KA; Kim DL; Chung CH; Park JH; Jang HC; Choi DS J Diabetes Investig; 2014 Nov; 5(6):701-8. PubMed ID: 25422771 [TBL] [Abstract][Full Text] [Related]
16. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. Ito D; Inoue K; Saito D; Hamaguchi K; Kaneko K; Sumita T; Inukai K; Inoue I; Shimada A Diabetes Ther; 2021 Dec; 12(12):3201-3215. PubMed ID: 34709582 [TBL] [Abstract][Full Text] [Related]
17. Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. Tajima N; Kadowaki T; Okamoto T; Sato A; Okuyama K; Minamide T; Arjona Ferreira JC J Diabetes Investig; 2013 Nov; 4(6):595-604. PubMed ID: 24843714 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146 [TBL] [Abstract][Full Text] [Related]
19. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Umpierrez G; Issa M; Vlajnic A Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436 [TBL] [Abstract][Full Text] [Related]
20. Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin. Jameshorani M; Sayari S; Kiahashemi N; Motamed N Open Access Maced J Med Sci; 2017 Dec; 5(7):955-962. PubMed ID: 29362626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]